Edwards Lifesciences Corp SEC Filings

Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported an option exercise and related share sale. On 01/09/2026, he exercised an Employee Stock Option for 1,019 shares of common stock at an exercise price of $59.2567 per share and acquired the underlying shares. On the same day, he sold 1,019 shares of common stock at a weighted average price of $85.7037 per share, in multiple trades executed between $85.45 and $85.95.

After these transactions, Lippis directly beneficially owned 22,001.9103 shares of Edwards Lifesciences common stock and 4,076 Employee Stock Options (right to acquire). The filing states that these transactions were carried out under a Rule 10b5-1 trading plan adopted by the reporting person on July 30, 2025.

Edwards Lifesciences reported insider transactions by its CVP, Strategy/Corp Development on 01/06/2026. The executive exercised an employee stock option for 11,340 shares of common stock at an exercise price of $59.2567 per share, then sold 2,632 shares at a weighted average price of $84.6206 and 8,708 shares at a weighted average price of $85.9793.

Following these transactions, the executive directly owned 31,870.2532 shares of common stock and also reported indirect ownership of 38,817.6991 shares through a 401(k) and 135,152 shares held by a trust. After the option exercise, 34,020 employee stock options remained beneficially owned. The filing notes that the transactions were carried out under a Rule 10b5-1 trading plan adopted on February 27, 2025.

Edwards Lifesciences insider Donald E. Bobo Jr. has filed a notice to sell company stock under Rule 144. The planned sale covers 45,360 shares of common stock through broker Charles Schwab & Co., Inc., with an aggregate market value of $3,885,715.00, and relates to an employee stock option exercise using a broker-assisted cashless exercise. The filing notes that 580,300,000 shares of Edwards Lifesciences common stock are outstanding and lists the New York Stock Exchange as the trading venue.

The notice also reports that over the past three months, the same insider sold 11,340 Edwards Lifesciences shares on 12/10/2025 for gross proceeds of $950,582.00 and 11,387 shares on 12/12/2025 for gross proceeds of $953,748.00. By signing the form, the seller represents that he is not aware of any undisclosed material adverse information about the company’s current or prospective operations.

Edwards Lifesciences (EW) reported insider activity by a senior executive. The company’s CVP, Strategy/Corp Development sold 5,486.1175 shares of common stock at $83.79 and 5,900 shares at $83.74 on 12/12/2025. On the same date, 7,100 shares were transferred as a gift at a stated price of $0.00. Following these transactions, the executive directly held 31,870.2532 shares of Edwards Lifesciences common stock, with additional indirect holdings of 38,817.6991 shares through a 401(k) plan and 135,152 shares held by a trust. The report notes that it reflects changes in beneficial ownership only and does not identify all securities of Edwards Lifesciences that the executive may beneficially own.

Edwards Lifesciences reported an insider transaction by a company officer serving as CVP, JAPAC. On 12/12/2025, the officer exercised an employee stock option for 1,019 shares of common stock at an exercise price of $59.2567 per share, then sold the same 1,019 shares in the open market at a weighted average price of $84.0287, with individual sale prices ranging from $83.58 to $84.46.

After these transactions, the officer directly held 22,001.9103 shares of Edwards Lifesciences common stock and 5,095 employee stock options. The filing states that the trades were carried out under a Rule 10b5‑1 trading plan adopted on July 30, 2025, which is a pre-arranged plan intended to allow insiders to sell shares over time according to preset instructions.

Edwards Lifesciences (EW) director reports a small stock sale. A company director filed to disclose the sale of 2,615 shares of Edwards Lifesciences common stock on 12/12/2025 at a price of $83.4109 per share, coded as an open market sale (transaction code "S").

After this transaction, the reporting person beneficially owns 30,948 shares of Edwards Lifesciences common stock in direct form. The filing is made by a single reporting person and expressly notes that it reflects only the change in beneficial ownership reported here and does not list all other securities of the company that the insider may own.

EW filed a Rule 144 notice covering a proposed sale of 5,900 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $494,066.00. The notice states that there were 580,300,000 common shares outstanding at the time of the filing. The shares to be sold were originally acquired from the issuer between December 12, 2021 and May 8, 2022 through restricted stock vesting and option exercises under registered equity plans, all paid for in cash. The seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.

Edwards Lifesciences (EW) insider plans modest Rule 144 sale of common stock. A holder intends to sell 2,615 shares of Edwards Lifesciences common stock through broker Charles Schwab & Co., Inc. on the NYSE, with an aggregate market value of $218,119.00. The filing notes that approximately 580,300,000 shares of common stock were outstanding, providing context for the small size of this planned sale. The shares to be sold were acquired on 05/03/2022 through a restricted stock lapse as equity compensation from Edwards Lifesciences Corporation.

Edwards Lifesciences executive plans modest stock sale under Rule 144. A notice was filed for the proposed sale of 5,487 shares of Edwards Lifesciences common stock through broker Charles Schwab & Co., Inc. on or about 12/12/2025 on the NYSE. The shares have an aggregate market value of $459,682.00 based on the price used in the notice, compared with 580,300,000 Edwards Lifesciences shares stated as outstanding.

The seller acquired these 5,487 shares on 05/08/2023 as equity compensation via RSU/PSU awards from Edwards Lifesciences Corporation. The filing also reports that, over the prior three months, the same individual sold 11,340 Edwards Lifesciences shares on 12/10/2025 for gross proceeds of $950,582.00. The signer confirms they are not aware of undisclosed material adverse information about the company’s operations.